Abstract
The morbidity and mortality of NSCLC remains high worldwide. However, the molecular mechanisms of NSCLC still largely unclear. Ets variant 5 (ETV5) is a transcription factor that found to be overexpressed in multiple cancers. However, the role of ETV5 in NSCLC remains unknown. We aim to explore the role and mechanisms of ETV5 in NSCLC development. The expression of ETV5 was evaluated in NSCLC tissues and cell lines. ETV5 overexpressing and downregulation cell lines were established according to the endogenous expression of ETV5. Functional studies were performed by transwell assay. The downstream targets of ETV5 were screened by PCR array and were confirmed by luciferase reporter assay. We found that overexpression of ETV5 indicates worse prognosis of NSCLC patients. Elevated ETV5 expression promotes NSCLC cell invasion and migration via transcriptional activates of TGFβ1. Therefore, ETV5/TGFβ signaling may serve as a therapeutic target for NSCLS patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- NSCLC:
-
Non-small cell lung cancer
- LUAD:
-
Lung adenocarcinoma
- LUSC:
-
Lung squamous cell carcinoma
- ETV5:
-
Ets variant 5
- ETS:
-
E twenty-six
- PEA3:
-
Polyoma enhancer activator 3
- EMT:
-
Epithelial-mesenchymal transition
- CTX:
-
Cetuximab
- MMP2:
-
Matrix metalloproteinase-2
- TGFβ1:
-
Transforming growth factor β1
- NRP1:
-
Neuropilin-1
- RCCD1:
-
RCC1 domain-containing protein 1
References
Alonso-Alconada L, Eritja N, Muinelo-Romay L, Barbazan J, Lopez-Lopez R, Matias-Guiu X, Gil-Moreno A, Dolcet X, Abal M (2014) ETV5 transcription program links BDNF and promotion of EMT at invasive front of endometrial carcinomas. Carcinogenesis 35:2679–2686. https://doi.org/10.1093/carcin/bgu198
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
Colas E, Pedrola N, Devis L, Ertekin T, Campoy I, Martínez E, Llauradó M, Rigau M, Olivan M, Garcia M, Cabrera S, Gil-Moreno A, Xercavins J, Castellvi J, Garcia A, Ramon S, Cajal G, Moreno-Bueno X, Dolcet F, Alameda J, Palacios J, Prat A, Doll X, Matias-Guiu M, Abal J, Reventos (2012) The EMT signaling pathways in endometrial carcinoma. Clin Transl Oncol 14:715–720. https://doi.org/10.1007/s12094-012-0866-3
Ding Z, Du W, Lei Z, Zhang Y, Zhu J, Zeng Y, Wang S, Zheng Y, Liu Z, Huang JA (2020) Neuropilin 1 modulates TGF–β1–induced epithelial–mesenchymal transition in non–small cell lung cancer. Int J Oncol 56:531–543. https://doi.org/10.3892/ijo.2019.4938
Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, Colás E, Llauradó M, Alazzouzi H, Planagumá J, Lohmann MA, Garcia J, Castellvi S, Ramon J, Cajal A, Gil-Moreno J, Xercavins F, Alameda J, Reventós (2008) Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol 108:221–229. https://doi.org/10.1016/j.jsbmb.2007.09.020
Du W, Tang H, Lei Z, Zhu J, Zeng Y, Liu Z, Huang JA (2019) Mir-335-5p inhibits TGF-β1-induced epithelial-mesenchymal transition in non-small cell lung cancer via ROCK1. Respir Res 20:225. https://doi.org/10.1186/s12931-019-1184-x
Kherrouche Z, Monte D, Werkmeister E, Stoven L, De Launoit Y, Cortot AB, Tulasne D, Chotteau-Lelievre A (2015) PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cells. Mol Oncol 9:1852–1867. https://doi.org/10.1016/j.molonc.2015.07.001
Miller M, Hanna N (2021) Advances in systemic therapy for non-small cell lung cancer. BMJ 375:n2363. https://doi.org/10.1136/bmj.n2363
Monge M, Colas E, Doll A, Gonzalez M, Gil-Moreno A, Planaguma J, Quiles M, Arbos MA, Garcia A, Castellvi J, Llaurado M, Rigau M, Alazzouzi H, Xercavins J, Alameda F, Reventos J, Abal M (2007) ERM/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer. Cancer Res 67:6753–6759. https://doi.org/10.1158/0008-5472.Can-06-4487
Oh S, Shin S, Janknecht R (2012) ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors. Biochim Biophys Acta 1826:1–12. https://doi.org/10.1016/j.bbcan.2012.02.002
Park SM, Hwang CY, Cho SH, Lee D, Gong JR, Lee S, Nam S, Cho KH (2019) Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells. Febs j 286:1305–1318. https://doi.org/10.1111/febs.14773
Puli OR, Danysh BP, McBeath E, Sinha DK, Hoang NM, Powell RT, Danysh HE, Cabanillas ME, Cote GJ, Hofmann MC (2018) The transcription factor ETV5 mediates BRAFV600E-Induced Proliferation and TWIST1 expression in papillary thyroid Cancer cells. Neoplasia 20:1121–1134. https://doi.org/10.1016/j.neo.2018.09.003
Qi T, Qu Q, Li G, Wang J, Zhu H, Yang Z, Sun Y, Lu Q, Qu J (2020) Function and regulation of the PEA3 subfamily of ETS transcription factors in cancer. Am J Cancer Res 10:3083–3105
Sizemore GM, Pitarresi JR, Balakrishnan S, Ostrowski MC (2017) The ETS family of oncogenic transcription factors in solid tumours. Nat Rev Cancer 17:337–351. https://doi.org/10.1038/nrc.2017.20
Su WZ, Yuan X (2018) LncRNA GASL1 inhibits tumor growth of non-small cell lung cancer by inactivating TGF-β pathway. Eur Rev Med Pharmacol Sci 22:7282–7288. https://doi.org/10.26355/eurrev_201811_16264
Tan AC, Tan DSW (2022) Targeted Therapies for Lung Cancer patients with oncogenic driver molecular alterations. J Clin Oncol 40:611–625. https://doi.org/10.1200/jco.21.01626
Wu J, He Z, Yang XM, Li KL, Wang DL, Sun FL (2017) RCCD1 depletion attenuates TGF-β-induced EMT and cell migration by stabilizing cytoskeletal microtubules in NSCLC cells. Cancer Lett 400:18–29. https://doi.org/10.1016/j.canlet.2017.04.021
Yang J, Du YM, Li B (2019) LncRNA BX357664 inhibits the proliferation and invasion of non-small cell lung cancer cells. Eur Rev Med Pharmacol Sci 23:660–669. https://doi.org/10.26355/eurrev_201901_16880
Yang SR, Schultheis AM, Yu H, Mandelker D, Ladanyi M, Büttner R (2022) Precision medicine in non-small cell lung cancer: current applications and future directions. Semin Cancer Biol 84:184–198. https://doi.org/10.1016/j.semcancer.2020.07.009
Acknowledgements
We thank all patients who have participated in this study. We thank the members of our group participated in this work.
Author information
Authors and Affiliations
Contributions
Dan Li and Yuan Wang drafted the manuscript, participated in research design, conducted experiments, and validated the data; Yanwei Shen, Hui Ren, Wang Li and Jin Yang participated in research design and conducted experiments; Yuan Wang contributed to the writing of the manuscript, discussing data and supervised the study. All authors performed data analysis and interpretation and read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Li, D., Shen, Y., Ren, H. et al. ETV5 transcriptionally activates TGFβ1 and promotes cancer cell invasion and migration of NSCLC. J Mol Histol 54, 419–426 (2023). https://doi.org/10.1007/s10735-023-10148-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10735-023-10148-3